Franklin Resources Inc. Increases Holdings in Jazz Pharmaceuticals PLC $JAZZ

Franklin Resources Inc. lifted its position in shares of Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) by 164.0% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 1,818,911 shares of the specialty pharmaceutical company’s stock after acquiring an additional 1,129,995 shares during the quarter. Franklin Resources Inc.’s holdings in Jazz Pharmaceuticals were worth $309,215,000 at the end of the most recent quarter.

Other institutional investors have also modified their holdings of the company. Hilltop National Bank purchased a new stake in shares of Jazz Pharmaceuticals during the 4th quarter worth approximately $36,000. LRI Investments LLC purchased a new stake in Jazz Pharmaceuticals in the 4th quarter valued at approximately $38,000. Danske Bank A S purchased a new stake in Jazz Pharmaceuticals in the 3rd quarter valued at approximately $40,000. Geneos Wealth Management Inc. lifted its stake in Jazz Pharmaceuticals by 57.6% in the 1st quarter. Geneos Wealth Management Inc. now owns 375 shares of the specialty pharmaceutical company’s stock valued at $47,000 after buying an additional 137 shares in the last quarter. Finally, Caitong International Asset Management Co. Ltd lifted its stake in Jazz Pharmaceuticals by 1,383.3% in the 3rd quarter. Caitong International Asset Management Co. Ltd now owns 356 shares of the specialty pharmaceutical company’s stock valued at $47,000 after buying an additional 332 shares in the last quarter. Hedge funds and other institutional investors own 89.14% of the company’s stock.

Jazz Pharmaceuticals Trading Down 1.2%

Shares of JAZZ opened at $229.19 on Wednesday. The stock has a fifty day moving average of $214.89 and a two-hundred day moving average of $187.75. The company has a debt-to-equity ratio of 0.95, a quick ratio of 1.85 and a current ratio of 2.04. The company has a market capitalization of $14.38 billion, a PE ratio of -11,453.77, a price-to-earnings-growth ratio of 0.22 and a beta of 0.32. Jazz Pharmaceuticals PLC has a fifty-two week low of $105.00 and a fifty-two week high of $243.32.

Jazz Pharmaceuticals (NASDAQ:JAZZ) last issued its quarterly earnings results on Tuesday, March 31st. The specialty pharmaceutical company reported $6.34 earnings per share for the quarter. The company had revenue of $1.07 billion during the quarter. Jazz Pharmaceuticals had a return on equity of 14.56% and a net margin of 0.66%. As a group, analysts forecast that Jazz Pharmaceuticals PLC will post 21.59 EPS for the current year.

Wall Street Analyst Weigh In

A number of equities research analysts recently issued reports on the company. Sanford C. Bernstein reaffirmed a “market perform” rating on shares of Jazz Pharmaceuticals in a research note on Tuesday. Truist Financial set a $256.00 target price on Jazz Pharmaceuticals and gave the company a “buy” rating in a research note on Tuesday. Wells Fargo & Company upped their target price on Jazz Pharmaceuticals from $250.00 to $265.00 and gave the company an “overweight” rating in a research note on Wednesday, May 6th. TD Cowen upped their target price on Jazz Pharmaceuticals from $220.00 to $275.00 and gave the company a “buy” rating in a research note on Wednesday, May 6th. Finally, Bank of America upped their target price on Jazz Pharmaceuticals from $263.00 to $275.00 and gave the company a “buy” rating in a research note on Wednesday, February 25th. Sixteen analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the stock. According to MarketBeat.com, Jazz Pharmaceuticals presently has a consensus rating of “Moderate Buy” and a consensus target price of $244.18.

Insider Buying and Selling at Jazz Pharmaceuticals

In other Jazz Pharmaceuticals news, Director Rick E. Winningham sold 2,741 shares of the business’s stock in a transaction on Friday, May 22nd. The stock was sold at an average price of $241.57, for a total value of $662,143.37. Following the completion of the transaction, the director directly owned 9,567 shares in the company, valued at approximately $2,311,100.19. The trade was a 22.27% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, Director Heather Ann Mcsharry sold 2,000 shares of the business’s stock in a transaction on Friday, May 22nd. The shares were sold at an average price of $241.00, for a total value of $482,000.00. Following the completion of the transaction, the director owned 18,449 shares of the company’s stock, valued at $4,446,209. This trade represents a 9.78% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. In the last three months, insiders sold 10,741 shares of company stock worth $2,287,143. Insiders own 4.30% of the company’s stock.

Jazz Pharmaceuticals Company Profile

Jazz Pharmaceuticals plc is a global biopharmaceutical company focused on developing and commercializing therapies in neuroscience and oncology. The company’s research and development efforts target unmet medical needs in sleep disorders, hematologic malignancies, rare neurological conditions and solid tumors. Jazz’s product portfolio includes therapies for narcolepsy, hepatic veno-occlusive disease, acute myeloid leukemia and other serious disorders.

Flagship products from Jazz Pharmaceuticals include Xyrem® (sodium oxybate) and Xywav® (calcium, magnesium, potassium, and sodium oxybates) for the treatment of cataplexy and excessive daytime sleepiness in patients with narcolepsy.